BRIDGEWATER, N.J., Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:

• Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 11:15 a.m. ET.
• Nasdaq 51^st Investor Conference held in association with Morgan Stanley in London on Wednesday, December 11, 2024, at 10:30 a.m. GT / 5:30 a.m. ET.

These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
(646) 812-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.

Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
This email address is being protected from spambots. You need JavaScript enabled to view it.

Gianna De Palma
Manager, Investor Relations
(973) 886-2236
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:

Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
This email address is being protected from spambots. You need JavaScript enabled to view it.